How should I initiate haloperidol (Haldol) intramuscular injection for acute agitation, including appropriate dosing, contraindications, and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Initiate Haloperidol Intramuscular Injection

For acute agitation in adults, start with haloperidol 5-10 mg IM, which can be repeated every 30-60 minutes as needed, with a maximum daily dose of 40 mg. 1

Initial Dosing by Patient Population

Adults (Standard Dosing)

  • Administer 5-10 mg IM for acute agitation 1
  • Repeat the same dose every 30-60 minutes if partial or no response 1
  • In severe agitation, doses may be repeated every 20-30 minutes until control is achieved 1
  • Maximum daily dose: 40 mg 1
  • Onset of action: 10-20 minutes IM, with peak effect at 60 minutes 1

Elderly or Frail Patients (≥65 years)

  • Start with 0.5-1 mg IM 2, 3
  • Low-dose haloperidol (≤0.5 mg) demonstrates similar efficacy to higher doses in older patients, with better outcomes including shorter length of stay and less restraint use 2
  • For severe delirium in palliative care: 0.5-2 mg every 1 hour PRN until episode controlled 3
  • Maximum recommended: 10 mg daily in frail or palliative patients 1

Pediatric Patients

  • Dose: 0.05-0.15 mg/kg IM (maximum 5 mg per dose) 1, 4
  • May be repeated hourly as needed 4
  • Ages 12-16 years: initial dose 10 mg 1
  • Ages 6-12 years: initial dose 2.5 mg (maximum daily 30 mg) 1

Critical Contraindications and Precautions

Absolute Contraindications

  • Known QTc prolongation or conditions predisposing to arrhythmias 5
  • Concurrent use with other QTc-prolonging agents 5
  • Parkinson's disease or Lewy body dementia 5

Monitoring Requirements

  • Monitor vital signs continuously, especially with repeated doses 1
  • Watch for QTc prolongation risk, particularly above 7.5 mg/day 1
  • Assess for extrapyramidal symptoms (EPS) after each dose 1
  • Have respiratory support immediately available 5

Management Algorithm for Acute Agitation

Step 1: Initial Assessment

  • Exclude medical causes of agitation (hypoxia, hypoglycemia, infection, substance withdrawal) 3
  • Assess for contraindications to haloperidol 5
  • Consider benzodiazepines as first-line for alcohol or substance-induced agitation 1

Step 2: First Dose Administration

  • Adults: 5-10 mg IM 1
  • Elderly: 0.5-1 mg IM 2
  • Pediatric: 0.05-0.15 mg/kg IM (max 5 mg) 1, 4

Step 3: Response Assessment (30 minutes post-dose)

  • If adequate response: Monitor and provide supportive care 1
  • If partial response: Repeat same dose 1
  • If no response: Repeat same dose and consider adding lorazepam 0.5-2 mg for refractory agitation 3

Step 4: Extrapyramidal Symptom Management

  • If EPS develop: reduce next dose by 50% 1
  • Consider prophylactic benztropine 1-2 mg IM if multiple doses needed 5
  • Dystonic reactions require immediate treatment with diphenhydramine 50 mg IM or benztropine 2 mg IM 5

Combination Therapy Considerations

Haloperidol Plus Benzodiazepines

  • For severe refractory agitation, combine haloperidol with lorazepam 0.5-2 mg 3
  • This combination is effective but increases sedation and respiratory depression risk 5, 6
  • Haloperidol 5 mg IM plus lorazepam 2 mg IM is a well-studied regimen 6
  • Monitor respiratory status closely when combining agents 5

Common Pitfalls to Avoid

Dosing Errors

  • Do not exceed 40 mg total daily dose 1
  • Avoid escalating doses above 15 mg, as higher doses do not improve efficacy and increase adverse effects 1
  • Do not use depot formulations (haloperidol decanoate) for acute agitation—these are only for maintenance therapy in stable patients 4

Safety Concerns

  • Haloperidol has been rarely associated with cardiac arrhythmia and sudden death, particularly at higher doses 5
  • The combination of IM olanzapine with benzodiazepines has been associated with fatalities and should be avoided 5
  • Intramuscular haloperidol causes significant EPS in 20-30% of patients 3, 5

Monitoring Failures

  • Failure to monitor for QTc prolongation with repeated dosing 1
  • Not recognizing early EPS, leading to patient distress and non-compliance 1
  • Inadequate respiratory monitoring when combining with benzodiazepines 5

Alternative Agents to Consider

While haloperidol remains effective, newer evidence suggests:

  • IM ziprasidone (10-20 mg) and IM olanzapine (10 mg) show faster onset and fewer EPS than haloperidol 3, 7
  • Both atypical agents demonstrated superior early efficacy (15-30 minutes) compared to haloperidol 7.5 mg IM 3, 7
  • Oral risperidone 2 mg plus lorazepam 2 mg is non-inferior to IM haloperidol 5 mg plus lorazepam 2 mg 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.